Total raised
$32.9M
Last: SAFE 2024-12
Stage
Series B
Founded
2014
Headcount
31
HQ
Caesarea
Sector
Health Tech & Life Sciences
About
Nitinotes is a clinical-stage company developing a revolutionary treatment for obesity. Its flagship product, the EndoZip, simplifies and speeds up endoscopic gastroplasty procedures, offering a widely available, minimally invasive, and effective solution for over 700 million patients with obesity class I & II for whom traditional bariatric surgery is not an option.
EndoZip is an automated and operator-independent, minimally invasive robotic suturing system, for safe and easy delivery of effective restrictive sutures to the stomach wall.
Nitinotes is conducting a series of pilot studies in various sites around the world aimed at fortifying both its clinical and economic cases.
Funding history · 4 rounds · $32.9M total
2024-12
SAFE
$9.3M
2023-09
Series B
$10.1M
2020-05
Series A
$7.1M
2017-03
Series A
$6.4M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Machinery & Robotics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 Patents
Tags
roboticsobesitynon-surgicalgastroenterologyminimally-invasiveendoscopysurgeonshospitalsmedical-devicesdoctorsclinicstreatments